Adding Maraviroc to Antiretroviral Therapy for Suboptimal CD4 T-Cell Recovery Despite Sustained Virologic Suppression
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Timothy J. Wilkin, MD, MPH
Cornell Clinical Research Site
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
29 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Alabama Therapeutics Crs (5801)
Birmingham, Alabama, United States
- Ucla Care Center Crs (601)
Los Angeles, California, United States
- Stanford Crs (501)
Palo Alto, California, United States
- Ucsd, Avrc Crs (701)
San Diego, California, United States
- Ucsf Aids Crs (801)
San Francisco, California, United States
- Georgetown University Crs (gu Crs) (1008)
Washington D.C., District of Columbia, United States
- Univ. of Miami Aids Crs (901)
Miami, Florida, United States
- the Ponce de Leon Ctr. Crs (5802)
Atlanta, Georgia, United States
- Northwestern University Crs (2701)
Chicago, Illinois, United States
- Ihv Baltimore Treatment Crs (4651)
Baltimore, Maryland, United States
- Johns Hopkins Adult Aids Crs (201)
Baltimore, Maryland, United States
- Boston Medical Center Actg Crs (104)
Boston, Massachusetts, United States
- Brigham and Women'S Hosp. Actg Crs (107)
Boston, Massachusetts, United States
- Massachusetts General Hospital Actg Crs (101)
Boston, Massachusetts, United States
- Washington University Crs (2101)
St Louis, Missouri, United States
- Cornell Crs (7804)
New York, New York, United States
- Ny Univ. Hiv/aids Crs (401)
New York, New York, United States
- Aids Care Crs (1108)
Rochester, New York, United States
- Univ. of Rochester Actg Crs (1101)
Rochester, New York, United States
- Unc Aids Crs (3201)
Chapel Hill, North Carolina, United States
- Duke Univ. Med. Ctr. Adult Crs (1601)
Durham, North Carolina, United States
- Univ. of Cincinnati Crs (2401)
Cincinnati, Ohio, United States
- Metrohealth Crs (2503)
Cleveland, Ohio, United States
- the Ohio State Univ. Aids Crs (2301)
Columbus, Ohio, United States
- Hosp. of the Univ. of Pennsylvania Crs (6201)
Philadelphia, Pennsylvania, United States
- Pittsburgh Crs (1001)
Pittsburgh, Pennsylvania, United States
- Vanderbilt Therapeutics Crs (3652)
Nashville, Tennessee, United States
- Peabody Health Ctr. Crs (31443)
Dallas, Texas, United States
- Houston Aids Research Team Crs (31473)
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2009
- Primary completion
- 31 Oct 2009
- Completion
- 30 Apr 2010
- Last update posted
- 12 Oct 2018
- Registered enrollment
- 34
- Registry id
- NCT00709111
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.